SNP Markers for Stroke Risk and Statin Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective genetic markers for predicting an individual's predisposition to stroke and variability in response to statin treatment, limiting personalized preventive and therapeutic strategies.
Innovation Solution
Identification of specific single nucleotide polymorphisms (SNPs) associated with stroke risk and statin response, enabling the development of diagnostic and prognostic reagents for predicting individual responses to statins and other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current genetic marker methods are used, then general stroke risk assessment is possible, but personalized prediction of stroke risk and statin response variability cannot be achieved
Solution Approach 1:
The patent segments the genetic information into multiple specific SNP markers (rs10455872, rs12511344, rs10757274, rs3900940, rs2200733, rs3814843) rather than using general genetic markers. Each SNP provides specific predictive information about stroke risk and statin response, enabling personalized predictions through combination of multiple segmented genetic indicators.
2Productivity
If general treatment protocols are used, then treatment can be applied to all patients, but effectiveness varies between individuals due to genetic differences
Solution Approach 1:
The patent changes the parameter of treatment selection from uniform protocol to genotype-specific protocol. By identifying specific SNP genotypes (e.g., AA, AG, GG at rs10455872), the treatment approach is customized to match the patient's genetic profile, thereby improving treatment effectiveness while managing complexity through systematic genotype-based classification.
3Reliability
If stroke prevention strategies are not personalized, then implementation is simple, but the ability to identify high-risk individuals and optimize statin therapy is limited
Solution Approach 1:
The patent performs preliminary genetic testing to identify specific SNP markers before implementing stroke prevention strategies. By detecting the presence or absence of specific alleles at defined SNP positions in advance, the system reliably predicts stroke risk and statin response, enabling optimized prevention protocols to be implemented subsequently.
Data Source
AI summary
The present invention provides compositions and methods based on genetic polymorphisms that are associated with vascular diseases such as stroke. In particular, the present invention relates to genetic polymorphisms that have utility for such uses as predicting disease risk or predicting an individual's response to a treatment such as statins, including groups of polymorphisms that may be used as a signature marker set for such uses, as well as nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.